Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Aggrenox

California says in a lawsuit filed Friday that pharmaceutical company Boehringer Ingelheim illegally paid rival Barr Laboratories over $120 million to delay the release of a generic version of the stroke-preventing drug Aggrenox.

SANTA ANA, Calif. – California says in a lawsuit filed Friday that pharmaceutical company Boehringer Ingelheim illegally paid rival Barr Laboratories over $120 million to delay the release of a generic version of the stroke-preventing drug Aggrenox.

Other defendants in the lawsuit filed by Orange County District Attorney Tony Rackauckas include Boehringer Ingelheim Pharma; Boehringer Ingelheim International; Teva Pharmaceuticals USA; Barr Pharmaceuticals; Barr Laboratories; Duramed Pharmaceuticals; and Duramed Pharmaceuticals Sales Corp.

Categories / Business, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...